Loading
NASDAQHealthcareMedical - Devices
Latest quote
$14.05
+$0.09 · +0.64%
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Previous close
$14.05
+$0.09 · +0.64%
After-hours
$14.00
−$0.05 · -0.36%
Sep 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Day range
Current $14.05
52-week range
Current $14.05
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
60
Fair Value
Sentiment
52
Mixed
Risk
64
High Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Day range
Current $14.05
52-week range
Current $14.05
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 36.97M USD | 31.39M USD | 23.96M USD | 20.55M USD | 16.3M USD |
| Cost of goods sold | 14.28M USD | 12.27M USD | 10.34M USD | 7.02M USD | 5.18M USD |
| Gross profit | 22.69M USD | 19.12M USD | 13.61M USD | 13.53M USD | 11.12M USD |
| Research and development | 13.9M USD | 12.39M USD | 11.71M USD | 10.89M USD | 9.28M USD |
| Selling, general, and administrative | 32.96M USD | 26.48M USD | 24.35M USD | 18.97M USD | 15.22M USD |
| Operating expenses | 46.86M USD | 38.87M USD | 36.06M USD | 29.86M USD | 24.5M USD |
| Interest income | 1.21M USD | 872K USD | 386K USD | — | — |
| Interest expense | 2.39M USD | — | — | 81K USD | 973K USD |
| Depreciation and amortization | 2.24M USD | 1.9M USD | 1.46M USD | 777K USD | 692K USD |
| Operating income | −24.16M USD | −19.75M USD | −22.45M USD | −16.33M USD | −13.37M USD |
| Net income | −25.54M USD | −18.91M USD | −22.09M USD | −16.44M USD | −14.41M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$23.50
67.26% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 27, 2016 | 1:40 | — | — |
Effective Jul 27, 2016
1:40
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI12.76M0.00%2.3T USD0.03%$377.6-0.56%
iShares Russell 2000 ETFIWM10.19M0.01%80.51B USD0.19%$294.67-0.45%
Vanguard Extended Market ETFVXF5.18M0.01%93.7B USD0.05%$241.35-0.54%
iShares Russell 2000 Growth ETFIWO3.7M0.03%14.7B USD0.24%$377.11-0.11%
Vanguard Russell 2000 ETFVTWO2.36M0.01%17.4B USD0.06%$119.14-0.40%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP1.7M0.06%2.68B USD0.20%$67.71+0.04%
iShares Micro-Cap ETFIWC1.36M0.09%1.49B USD0.60%$195.17-0.74%
State Street SPDR S&P Health Care Equipment ETFXHE1.35M0.76%178.93M USD0.35%$92.37-1.94%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPiShares Micro-Cap ETFIWCState Street SPDR S&P Health Care Equipment ETFXHEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
